| methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg. |
NCT00269789: A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children |
|
|
| Completed | 3 | | US | Ritalin, OROS Methylphenidate HCl, Placebo | Alza Corporation, DE, USA | Attention Deficit Hyperactivity Disorder | | 05/98 | | |
NCT00269776: An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | | US | Placebo, OROS (methylphenidate HCl), Ritalin (methylphenidate) | Alza Corporation, DE, USA | Attention Deficit Hyperactivity Disorder | | 01/99 | | |
NCT00269802: A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | | US | OROS methylphenidate HCl, Ritalin, Placebo | Alza Corporation, DE, USA | Attention Deficit Hyperactivity Disorder | | 02/99 | | |
NCT00269815: Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | | US | methylphenidate HCl | Alza Corporation, DE, USA | Attention Deficit Hyperactivity Disorder | | 12/99 | | |
NCT00249353: An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 220 | US | methylphenidate hydrochloride | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Attention Deficit Disorder With Hyperactivity | | 10/02 | | |
NCT00304681: An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children |
|
|
| Completed | 3 | 147 | US | OROS*-Methylphenidate | Janssen-Ortho Inc., Canada | Attention Deficit Hyperactivity Disorder | | 02/04 | | |
NCT00485550: Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy |
|
|
| Completed | 3 | 14 | US | Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | | 03/05 | | |
NCT00444574: Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD |
|
|
| Completed | 3 | 282 | US | Methylphenidate Transdermal System, MTS, Placebo, Sham treatment, Concerta, Methylphenidate HCL | Noven Therapeutics | Attention Deficit Hyperactivity Disorder | 06/05 | 06/05 | | |
NCT00246207: CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults |
|
|
| Completed | 3 | 32 | US | CONCERTA (OROS methylphenidate hydrochloride) | Janssen-Ortho Inc., Canada | Attention Deficit Disorder With Hyperactivity | | 12/05 | | |
NCT00301639: A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults |
|
|
| Completed | 3 | 40 | US | OROS methylphenidate hydrochloride, methylphenidate hydrochloride | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Healthy Volunteers | 12/05 | 12/05 | | |
NCT00246233: CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder. |
|
|
| Completed | 3 | 145 | US | methylphenidate | Janssen-Ortho Inc., Canada | Depressive Disorder, Major | | 04/06 | | |
NCT00246220: A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder. |
|
|
| Completed | 3 | 402 | Europe | methylphenidate hydrochloride | Janssen Pharmaceutica N.V., Belgium | Attention Deficit Disorder With Hyperactivity | | 11/06 | | |
NCT00326391: A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 229 | US | methylphenidate hydrochloride extended-release tablets | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Attention Deficit Disorder With Hyperactivity | 12/06 | 12/06 | | |
NCT00302393: Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults |
|
|
| Completed | 3 | 20 | US | OROS methylphenidate hydrochloride, methylphenidate hydrochloride | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Healthy | 02/07 | 02/08 | | |
NCT00326300: A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 560 | US | methylphenidate hydrochloride extended-release tablets | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Attention Deficit Hyperactivity Disorder | | 08/07 | | |
NCT00307684: Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 155 | Europe | double blind placebo, double blind PR OROS methylphenidate, open label PR OROS methylphenidate | Janssen-Cilag International NV | Attention Deficit Disorder With Hyperactivity | 07/08 | 07/08 | | |
NCT00714688 / 2007-002111-82: A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 279 | Europe | prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg, Placebo | Janssen-Cilag International NV | Attention Deficit/ Hyperactivity Disorder | 04/09 | 04/09 | | |
NCT00482313 / 2006-002553-80: Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 30 | Europe | PR OROS Methylphenidate, Concerta, Placebo | Psychiatry Karolinska, Ministry of Health and Social Affairs, Sweden, Region Stockholm | Attention Deficit Hyperactivity Disorder | 04/10 | 04/10 | | |
NCT00376675: Methylphenidate in Treating Patients With Fatigue Caused by Cancer |
|
|
| Completed | 3 | 148 | US | methylphenidate hydrochloride, placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Fatigue, Unspecified Adult Solid Tumor, Protocol Specific | 06/10 | 06/10 | | |
NCT00763971 / 2008-000679-90: Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 |
|
|
| Completed | 3 | 336 | Europe | Lisdexamfetamine Dimesylate (LDX), Vyvanse™, Methylphenidate Hydrochloride, Concerta®, OROS MPH, Placebo | Shire | ADHD | 03/11 | 03/11 | | |
NCT01323192: An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 284 | Japan | JNS001, Placebo | Janssen Pharmaceutical K.K. | Attention-Deficit Hyperactivity Disorder | 04/12 | 04/12 | | |
NCT01357993: A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder |
|
|
| Completed | 3 | 253 | Japan | JNS001 | Janssen Pharmaceutical K.K. | Attention-Deficit / Hyperactivity Disorder | 03/13 | 03/13 | | |
NCT00516269: Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients |
|
|
| Terminated | 3 | 42 | US | Methylphenidate, Concerta, Ritalin, Methylphenidate Hydrochloride, Placebo | M.D. Anderson Cancer Center, Ortho-McNeil Janssen Scientific Affairs, LLC | Breast Cancer, Fatigue, Gastrointestinal Cancer | 12/13 | 12/13 | | |
NCT01599975: A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV |
|
|
| Unknown status | 3 | 40 | US | Long acting methylphenidate, Concerta, Matched placebo, Matched placebo as supplied by Johnson and Johnson | University of California, Los Angeles | HIV Dementia | 05/14 | 09/14 | | |
2012-004298-20: The effect of methylphenidate on executive functioning in amphetamine dependent individuals with ADHD |
|
|
| Ongoing | 3 | 24 | Europe | methylphenidate, Capsule, Concerta 36 mg depottablett | Stockholm Centre for Dependency Disorders, Stockholm Centre for Dependency Disorders | Amphetamine dependence, Patients who fulfil DSMIV/5 criteria for amphetamine dependence, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2004-000730-37: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder. |
|
|
| | 3 | 45 | Europe | Concerta XL 18 mg, Concerta XL 36 mg, Concerta XL 54 mg, CAS:113-45-1, N/A, Concerta, Concerta | Janssen-Cilag Medical Affairs EMEA, Janssen-Cilag A/S | Attention Deficit Hyperactivity Disorder (ADHD) | | 10/06 | | |
2005-004037-18: An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 80 | Europe | CONCERTA 18 mg, CONCERTA 36 mg, CONCERTA 54 mg, Concerta 18 mg Retardtabletten, CONCERTA 36 mg Retardtabletten, CONCERTA 54 mg Retardtabletten, Concerta 18 mg Retardtabletten, CONCERTA 36 mg Retardtabletten, CONCERTA 54 mg Retardtabletten | Janssen-Cilag Medical Affairs EMEA, Janssen-Cilag EMEA | Attention Deficit-Hyperactivity Disorder (ADHD) | | 07/08 | | |
NCT01109849: Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth |
|
|
| Completed | 3 | 230 | US | behavior therapy, behavior modification, Extended release (ER) methylphenidate product, Concerta, OROS-MPH, Central Nervous Systemt (CNS) stimulants, monitoring, monitoring arm, drug holiday, Ritalin based product, CNS stimulants, caloric supplement | Florida International University | ADHD, Growth | 04/16 | 04/16 | | |
NCT02502799: Intervention for Teens With ADHD and Substance Use |
|
|
| Terminated | 3 | 158 | US | Brief Early Intervention, BEI, Teen Intervene, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate, Concerta | Florida International University | Attention Deficit Hyperactivity Disorder | 08/21 | 08/21 | | |
| Recruiting | 3 | 150 | Europe | Concerta, Placebo | Stéphanie Baggio, University of Lausanne, University of Geneva, Switzerland, Netherlands Institute for the Study of Crime, School of Health Sciences Fribourg | ADHD | 10/25 | 10/26 | | |
NCT02215538: OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD |
|
|
| Completed | 2/3 | 47 | US | OROS methylphenidate, concerta, Placebo | University of Utah, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Attention Deficit Hyperactivity Disorder | 02/06 | 06/06 | | |
NCT01853280: L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults |
|
|
| Completed | 2/3 | 47 | US | L-methylfolate, Deplin®, OROS-Methylphenidate, Concerta®, Placebo | Massachusetts General Hospital, Pamlab, Inc. | Attention Deficit Hyperactivity Disorder | 02/17 | 09/17 | | |
